Anupama Chaturvedi

Cardiovascular disorders require long-term treatment and continuous medication adherence to achieve effective disease management. Carvedilol is an important antihypertensive and cardioprotective drug widely used in the treatment of hypertension and heart failure. However, its therapeutic performance may be affected by poor aqueous solubility, extensive first-pass metabolism, and limited oral bioavailability. These challenges highlight the need for a drug delivery system capable of providing prolonged drug release and maintaining therapeutic drug levels for an extended period. The present study focused on the development of Carvedilol-loaded microspheres using the ionotropic gelation technique. Sodium alginate was selected as the polymeric carrier because of its biocompatibility, biodegradability, and gel-forming ability in the presence of calcium ions. Microspheres were prepared by ionic cross-linking and subsequently evaluated for their physicochemical and release characteristics. Various parameters, including percentage yield, particle size, drug entrapment efficiency, flow properties, and in vitro drug release, were assessed to determine the suitability of the developed formulations. The prepared microspheres demonstrated satisfactory formulation characteristics with effective drug incorporation and controlled-release behavior. Drug release was prolonged due to the formation of a cross-linked polymeric matrix, indicating the potential of the system to sustain drug delivery over an extended period. The optimized formulation exhibited desirable pharmaceutical properties and a release profile suitable for sustained therapeutic action. The study demonstrates that ionotropically gelled Carvedilol microspheres can be successfully developed as a sustained-release delivery system. Such a formulation may contribute to improved therapeutic effectiveness, reduced dosing frequency, and enhanced patient convenience during long-term cardiovascular therapy.

Among the drugs used in long-term cardiovascular management, carvedilol occupies a special position owing to its combined non-selective beta-blockade and alpha-1 receptor antagonism. However, turning this pharmacological advantage into consistent clinical benefit is not straightforward. The molecule belongs to BCS Class II, meaning it crosses biological membranes readily but barely dissolves in physiological fluids. On top of that, extensive hepatic extraction during the first pass through the liver trims oral bioavailability to somewhere between 25 and 35 percent, and an elimination half-life of only 6 to 10 hours forces patients to take the drug multiple times a day. Together, these characteristics create the conditions for erratic plasma concentrations, missed doses, and avoidable side effects. Encapsulating carvedilol within polymer-matrix microspheres is a strategy with growing experimental support: the polymer network acts as a physical throttle on drug escape, stretching the release window well beyond what any immediate-release tablet can offer. This article brings together evidence published between 2016 and 2025 on how microsphere formulations of carvedilol are built, what polymers are chosen and why, how the finished particles are tested, and what the most informative recent studies have found. Across this body of work, entrapment efficiencies consistently exceed 75 percent when formulation conditions are properly optimised, and release profiles extending to 12 hours or beyond are regularly achieved. Floating, pH-sensitive, and mucoadhesive variants each address specific absorption or tolerability concerns, broadening the design toolbox available to formulators.